1. Home
  2. CATO vs CTSO Comparison

CATO vs CTSO Comparison

Compare CATO & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cato Corporation (The)

CATO

Cato Corporation (The)

N/A

Current Price

$2.97

Market Cap

61.6M

ML Signal

N/A

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

N/A

Current Price

$0.73

Market Cap

45.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CATO
CTSO
Founded
1946
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.6M
45.7M
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
CATO
CTSO
Price
$2.97
$0.73
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
48.1K
67.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
17.09
N/A
EPS
0.25
N/A
Revenue
$649,806,000.00
$22,503,908.00
Revenue This Year
N/A
$7.29
Revenue Next Year
N/A
$8.91
P/E Ratio
$11.92
N/A
Revenue Growth
N/A
48.53
52 Week Low
$2.19
$0.60
52 Week High
$4.92
$1.39

Technical Indicators

Market Signals
Indicator
CATO
CTSO
Relative Strength Index (RSI) 44.76 54.78
Support Level $2.81 $0.62
Resistance Level $3.22 $0.84
Average True Range (ATR) 0.18 0.04
MACD 0.00 0.01
Stochastic Oscillator 17.31 59.46

Price Performance

Historical Comparison
CATO
CTSO

About CATO Cato Corporation (The)

The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: